NewsRoom Articles - Page 106 of 220

ThursdaySep 15, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs The company is currently developing a treatment for concussion, a condition that currently does not have an FDA-approved treatment despite having both short- and long-term consequences Through animal studies, Odyssey has so far evidenced that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate the swelling, oxidative stress, and inflammation in the brain caused by concussion while simultaneously restoring proper blood flow Odyssey is currently undertaking Phase 1 clinical studies with plans underway to commence its Phase 2 trial…

WednesdaySep 14, 2022 11:05 am

Study Finds Depression Symptoms in Partners Caring for Dementia Patients May Start Long Before Cognitive Decline

A new study has found that symptoms of depression among older individuals who care for partners with cognitive impairments can present up to a decade before a routine screening can detect the first signs of their partner’s dementia. The research was carried out by scientists at the University of Michigan, including Geoffrey Hoffman, an assistant professor of nursing at the University of Michigan School of Nursing. These findings don’t align with current belief that there are significant increases in care received right after dementia begins developing. Hoffman stated that while conventional thinking suggested that the burden of caregiving and poor…

TuesdaySep 13, 2022 1:53 pm

Study Finds Hepatitis C Drugs May Help Alleviate Symptoms of PTSD

Post-traumatic stress disorder (PTSD) is a debilitating mental condition that affects roughly 3.5% of American adults each year. Around 1 in 11 people will be diagnosed with the condition within their lifetime, with women being two times more likely to develop PTSD than men. PTSD is more prevalent in veterans, children and people who have been through traumatic events. But even though the condition affects millions of Americans each year, the FDA has only approved two drugs to treat it — paroxetine and sertraline — and these substances are only mildly effective against PTSD symptoms. For the past two years,…

TuesdaySep 13, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas Glioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosis CNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and…

MondaySep 12, 2022 1:31 pm

Researchers Find Cases of Osteosarcoma More Prevalent in Blacks

Osteosarcoma is a rare bone cancer that most often affects the long bones in the legs and arms. Although it occurs most often in young adults, older adults and younger children are also at risk of developing osteosarcoma. This type of bone cancer is often characterized by bone pain and swelling, with younger people usually experiencing these symptoms around the upper arms or knees. The National Organization for Rare Disorders estimates that some 750 to 1,000 individuals are diagnosed with the disease each year in the United States with some 450 of them being the age of 20. Furthermore, recent…

MondaySep 12, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans Odyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients Each year, medical costs in the United States for concussions total $20 billion ($400 billion worldwide). There is a significant unmet medical need for treatments for concussions in the medical landscape, with most diagnosed…

FridaySep 09, 2022 12:04 pm

Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players

Despite lacrosse being a noncontact sport, head impacts and incidental concussions are common occurrences during games. The noncontact sports rules also seep into the mandated protective equipment allowed for girls’ lacrosse, which is limited to eyewear and mouthguards. Girls’ lacrosse has increasingly grown in popularity this past decade, with figures showing that prior to the pandemic, its adoption in America grew by more than 50%. While the use of soft-shell headgear has been permitted in the game since 2017, using headgear is still a bone of contention in a number of states. Critics have even argued that the use of…

FridaySep 09, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cure CNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, Berubicin Berubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclines CNS has shown evidence…

ThursdaySep 08, 2022 12:10 pm

Researchers Find Link Between Steroidal Allergy Treatments, Decreased Brain Function

Pharmaceutical medications may have allowed us to beat innumerable diseases and significantly increase our lifetimes, but they are not without risk. One chief complaint about most pharmaceuticals is that while they are often effective at mitigating the diseases they are deployed against, they often cause unwanted side effects. These side effects can range from drowsiness, dry mouth, and skin rashes to severe, life-threatening side effects. According to a previous study by the Federal Agency for Healthcare Research and Quality, an estimated 4.5 million patients visit emergency rooms or doctors’ offices each year due to adverse drug effects. Building on the…

WednesdaySep 07, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage The pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the company’s use of its patent-pending breath-propelled intranasal drug administration device The company believes that the intranasal drug/delivery combination will be instrumental in the success of the PRV-002 drug candidate in planned Phase II/III…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

Study Finds Depression Symptoms in Partners Caring for Dementia Patients May Start Long Before Cognitive Decline

Study Finds Hepatitis C Drugs May Help Alleviate Symptoms of PTSD

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

Researchers Find Cases of Osteosarcoma More Prevalent in Blacks

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

Researchers Find Link Between Steroidal Allergy Treatments, Decreased Brain Function

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search